Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

    ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

    17 hours ago | ViiV Healthcare
  • New York Governor Announces PrEP Assistance Program

    New York Governor Andrew Cuomo announced last week a new pre-exposure prophylaxis assistance program that proponents say will help to end the AIDS epidemic in the state by 2020. The country's first-of-its-kind program will help at-risk groups, including gay and bi men and transgender women, obtain testing, medication, and counseling.

    20 hours ago | HIVPlusMag
  • World Health Assembly: Experts discuss delinking drug R&D costs from pricing to make them affordable

    The problem of drug prices eating up national health budgetscame up at the annual World Health Assembly, which took place from 18-26 May. Last week, a panel of experts discussed the merits of lowering those prices by delinking research and development costs from pricing.

    21 hours ago | Intellectual Property Watch
  • NHS England accused of interference over hepatitis C drug

    Officials at NHS England have been accused of interfering in a process to decide whether a drug which can cure Hepatitis C should be made available to patients on the health service.

    22 hours ago | Channel 4 News
  • Fighting HIV where no-one admits it's a problem

    For years Russia has remained remarkably silent on the challenge it faces from HIV and Aids. Now that silence has been broken by an epidemiologist who has been working in the field for more than two decades - and he calls the situation "a national catastrophe".

    20 May 2015 | BBC
  • Moscow police detain HIV activists over drug cost picket

    Police in Moscow have briefly detained eight activists who picketed outside the presidential administration's headquarters to protest the high cost of HIV treatments in Russia.

    14 May 2015 | Yahoo News
  • Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs

    The ongoing debate over the cost of prescription drugs took another twist as U.S. Sen. Bernie Sanders (I-VT.) has asked the U.S. Department of Veterans Affairs to use emergency powers to break – or override – the patents on high-priced hepatitis C drugs.

    13 May 2015 | Wall Street Journal (blog)
  • WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

    WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others.

    11 May 2015 | World Health Organization
  • Gilead: Stop Blocking Access to Hepatitis C Treatment

    On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.

    05 May 2015 | Treatment Action Group
  • Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

    Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

    05 May 2015 | Hep C Coalition
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.